Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 1 of the 6 sources its claims cite were checked for support.
Abstract
BACKGROUND: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple myeloma is needed. METHODS: In this phase 3 trial, we randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple myeloma to receive either subcutaneous daratumumab combined with VRd induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group). The primary end point was progression-free survival. Key secondary end points were a complete response or better and minimal residual disease (MRD)-negative status. RESULTS: At a median follow-up of 47.5 months, the risk of disease progression or death in the D-VRd group was lower than the risk in the VRd group. The estimated percentage of patients with progression-free survival at 48 months was 84.3% in the D-VRd group and 67.7% in the VRd group (hazard ratio for disease progression or death, 0.42; 95% confidence interval, 0.30 to 0.59; P<0.001); the P value crossed the prespecified stopping boundary (P = 0.0126). The percentage of patients with a complete response or better was higher in the D-VRd group than in the VRd group (87.9% vs. 70.1%, P<0.001), as was the percentage of patients with MRD-negative status (75.2% vs. 47.5%, P<0.001). Death occurred in 34 patients in the D-VRd group and 44 patients in the VRd group. Grade 3 or 4 adverse events occurred in most patients in both groups; the most common were neutropenia (62.1% with D-VRd and 51.0% with VRd) and thrombocytopenia (29.1% and 17.3%, respectively). Serious adverse events occurred in 57.0% of the patients in the D-VRd group and 49.3% of those in the VRd group. CONCLUSIONS: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.).
Overview
CoChat Summary
## TL;DR
The supplementary appendix for the PERSEUS trial describes a randomized comparison of subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone (D-VRd) versus VRd alone in transplant-eligible patients with newly diagnosed multiple myeloma. It mainly provides endpoint definitions, statistical methods, eligibility criteria, subgroup results, and safety tables, but not the full primary efficacy narrative.
## Key findings
- The trial’s primary endpoint was progression-free survival; key secondary endpoints were overall complete response or better, overall minimal residual disease (MRD)-negativity, and overall survival.
- At the interim analysis, the primary endpoint was tested at an exact two-sided significance level of 0.0126, determined by 153 progression-free survival events under an Hwang-Shih-DeCani alpha-spending function.
- In prespecified subgroup analyses, D-VRd showed higher overall complete response or better rates and MRD-negativity rates across most reported subgroups; for example, MRD-negativity was 71.1% vs 45.9% in men, 81.3% vs 49.7% in women, and 78.2% vs 46.8% in patients younger than 65 years.
- Safety tables report serious adverse events in 57.0% of D-VRd patients (200/351) versus 49.3% of VRd patients (171/347); infections were the most common serious adverse event category (35.0% vs 27.4%).
## Methods
- Randomized PERSEUS study in transplant-eligible patients with newly diagnosed multiple myeloma; eligible patients were 18 to 70 years old and had ECOG performance status 0 to 2 and specified laboratory/organ-function criteria.
- The appendix specifies an intention-to-treat framework for efficacy endpoints and a safety population of patients who received at least one dose of study treatment; sample sizes in the safety tables were 351 for D-VRd and 347 for VRd.
- Main analyses included progression-free survival with two interim analyses and a final analysis, plus hierarchical testing of key secondary endpoints to control family-wise type I error; subgroup analyses are shown for complete response or better and MRD-negativity.
## Limitations
- The appendix text itself does not report the main trial’s headline efficacy results (for example, hazard ratios or median progression-free survival), so those outcomes cannot be summarized from this text alone.
- The subgroup forest plots note that the widths of confidence intervals were not adjusted for multiplicity and cannot be used to infer treatment effects.
- Evident from the provided text: this is a supplementary appendix only, so it is incomplete as a standalone paper summary.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
1 Valid · 1 Not valid · 3 Not checked · 42 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Standard risk | 182/266 (68.4) | 234/264 (88.6) | | 3.60 (2.27–5.70) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Non-IgG | 73/96 (76.0) | 72/78 (92.3) | | 3.78 (1.45–9.83) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| ≥65 years | 62/87 (71.3) | 77/94 (81.9) | | 1.83 (0.91–3.68) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Male | 94/205 (45.9) | 150/211 (71.1) | | 2.90 (1.94–4.35) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| <65 years | 186/267 (69.7) | 235/261 (90.0) | | 3.94 (2.43–6.37) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
24 more claims
Create a free account to see all 47 claims and every source verdict.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 11
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The quadruplet regimen of daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd) has recently emerged as standard of care option for initial therapy in transplant eligible patients with newly diagnosed myeloma.101,111”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The role of daratumumab in patients who received it as part of frontline therapy is unclear.101,152”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daratumumab, an anti-CD38–targeting monoclonal antibody (mAb), is a cornerstone of standard-of-care MM regimens with demonstrated survival benefit across all lines.9–14”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Self-citationKrejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationGlobal Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2128 · Cited by 631
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Research works printed but not linked: 1
- 7. Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 2016;43:676-81.
Cited by
Items 401–500 of 589
Current and Future Approaches for the Treatment of Plasma Cell Leukemia
Fortuna, G. G., Voorhees, P. M., Usmani, S. Z., & Sborov, D. W. (2025) · Advances in Oncology · doi:10.1016/j.yao.2025.02.002
Pham, M. Q., & Croizier, C. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.02.013
Daratumumab for high-risk smoldering multiple myeloma – Are we there yet?
Lal, B. M., & Hadidi, S. A. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115391 · Cited by 1
Podar, K. (2025) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-025-01030-x
“Importantly, follow-up analyses of several pivotal clinical trials including MAIA, ALCYONE, POLLUX, CASTOR, and PERSEUS demonstrate that sustained MRD negativity ( ≥ 12 months) has an even higher prognostic value than MRD negativity measured at a single timepoint [29–32].”
InfluentialBal, S., Magnusson, T., Ravi, G., Giri, S., Godby, K. N., Dhakal, B., Callander, N. S., Silbermann, R. W., Dholaria, B., Reddy, V., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01252-6 · Cited by 2
T cell phenotype and clonality changes in myeloma patients with short overall survival
Behsen, A. D., Vandsemb, E. N., Slørdahl, T. S., Dybkær, K., Jakobsen, M. Z., Kashif, M., Lund, J., Luong, V., Olsnes, A. M., Waage, A., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.181096 · Cited by 2
“Daratumumab-based combinations, for instance, are a common treatment today (44, 45), but only 3 patients in our cohort received them.”
Xu, H., She, Q., Zhang, B., Zhang, S., & Xie, L. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1453367
“Innovations such as CAR-T cell therapy and cutting-edge targeted medications, including Bruton’s tyrosine kinase inhibitors, Bcl-2 inhibitors, and CD38 monoclonal antibodies, have the potential to significantly boost survival rates and the quality of life for patients (22–25).”
Right time: stopping multiple myeloma maintenance
McCarthy, P. L., & Mohammadpour, H. (2025) · Blood · doi:10.1182/blood.2025028814
Hilfe bei der Wahl der bestmöglichen Erstlinientherapie
Mertens, L., Hentrich, M., & Högner, M. (2025) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-025-0955-4
“In der PERSEUS-Studie wurden als Konsolidierung zwei weitere Zyklen DaraVRd appliziert, gefolgt von einer Daratumumab/ Lenalidomid-Erhaltungstherapie [11].”
A natural head start to MRD negativity in multiple myeloma
Meermeier, E. W. (2025) · Blood · doi:10.1182/blood.2025028710
Review Article: Immunotherapy for Pediatric Malignancies: Benefits and Beyond
Soumyakrishnan, S., Ayariga, J. A., Prakash, N., Gangavarapu, R. R., Sreepriya, M., & Nagaraju, G. P. (2025) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2025060148
Chalopin, T., Decaux, O., Hulin, C., Perrot, A., Macro, M., Royer, B., Bastie, J.-N., Bobin, A., Jacquet, C., Mohty, M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.07.009
Self-citationMedhekar, R., Clark, L., Gautam, S., & Cortoos, A. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2537813
Maligne aandoeningen van het lymfatische systeem
de Jong, D., Tonino, S. H., Kroeze, L. I., Plattel, W. J., Aleman, B. M. P., & van de Donk, N. W. C. J. (2025) · doi:10.1007/978-90-368-3138-3_30
Self-citationOptimal control of multiple myeloma assuming drug resistance and off-target effects
Lefevre, J., Lawson, B., Burrage, P., Donovan, D. M., & Burrage, K. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012225
“More recently combination therapies using Dara have also been developed [11].”
Nivedita, K., Prakash, S., Sahu, A., Mukherjee, S., & Mishra, D. (2025) · Journal of Laboratory Physicians · doi:10.25259/jlp_30_2025
Yaseen, A., Ma’koseh, M., Alamoush, A., Zayed, A., Ribie, M. K., Alzubi, M., Alrawabdeh, J. A., Mubaydeen, T., Alfar, R., Da'Na, W. K., et al. (2025) · Blood Global Hematology · doi:10.1016/j.bglo.2025.100024
Early Attrition and Excess Mortality in Multiple Myeloma: Lessons From Real-World Evidence
Sathian, B., Ali, S. M., Iqbal, J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.010
Deep dive into shallow myeloma cell pool
Samur, M. (2025) · Blood · doi:10.1182/blood.2025029778
CDA-AMC (2025) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2025.1197
Lipof, J. J., Chung, A., Kumar, A. D., Pan, D., & Chari, A. (2025) · The Hematologist · doi:10.1182/hem.v22.5.2025510
The role of maintenance therapy and its cessation in patients with multiple myeloma
Sneider, A. P., & Derman, B. A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2551785 · Cited by 3
“…studies were associated with superior PFS, there was no second randomization to determine the added benefit of daratumumab to R in maintenance [30,31]. two important ongoing studies may help to decipher the benefit of adding an anti-cD38 monoclonal antibody to R in the era of quadruplet therapy.”
From Physician-Driven to Patient-Centered: Transforming Multiple Myeloma Care Decisions
Thakur, R., & Hadidi, S. A. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00712
Angiogenesis in Multiple Myeloma: 25 Years of Research in This Field
Ribatti, D. (2025) · European Journal Of Haematology · doi:10.1111/ejh.70023 · Cited by 1
Novellis, D. D., Palmieri, S., Rocco, S., Derudas, D., Pepa, R. D., Roccotelli, D., Esposito, D., Masucci, C., Gigliotta, E., Barone, M. L., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06572-y
Use of CD38 Antibodies in High-Risk Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Bhutani, D., Liu, Y. K., Chakraborty, R., Hughes, M. S., Lentzsch, S., & Rubinstein, S. M. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.04.016
Self-citationPerspectives on Newly Diagnosed Myeloma Treatment and Emerging Challenges
Touzeau, C., & Moreau, P. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0280
Self-citationGay, F., Marchetti, E., & Bertuglia, G. (2025) · Kompass Onkologie · doi:10.1159/000547999
Self-citationIkeda, S., Kobayashi, T., Kitadate, A., Yamashita, T., Watanabe, A., Fujishima, N., Yoshioka, T., Kume, M., Kameoka, Y., Kitabayashi, A., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5894-25
Merz, M. (2025) · Blood · doi:10.1182/blood.2025029889
Mel, S. D., Tso, A. C. Y., Soekojo, C. Y., Ooi, M. G. M., Lim, C. C., Teo, C., Chen, Y. X., Tan, M. S. Y., Manjeri, A., Lee, Z. Y., et al. (2025) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202532 · Cited by 1
Czernilofsky, F., & Raab, M. S. (2025) · Trillium Krebsmedizin · doi:10.47184/tk.2025.05.1
Multiples Myelom: Hochrisikomyelom Therapiestrategien und neue Ansätze
Artzenroth, C., Al-Bazaz, M., Kosch, R., Schaefers, C., Weisel, K. C., & Leypoldt, L. B. (2025) · Trillium Krebsmedizin · doi:10.47184/tk.2025.05.2
Hentrich, M., & Straka, C. (2025) · Trillium Krebsmedizin · doi:10.47184/tk.2025.05.3
More is not always more for older patients with multiple myeloma
Shain, K. H. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00357-2
Newly Diagnosed High‐Risk Multiple Myeloma: Outcomes and Management
Yasar, F. Z., & Gorshein, E. (2025) · Advances in Hematology · doi:10.1155/ah/6622365 · Cited by 1
“Importantly, predetermined subgroup analyses demonstrated a consistent PFS advantage for DVRd over VRd across clinically relevant subgroups, including patients with high-risk cytogenetics, supporting the efcacy of this quadruplet regimen even in adverse-risk disease [25].”
Mel200 or BuMel conditioning in myeloma: is there a winner?
Reece, D. E. (2025) · Blood · doi:10.1182/blood.2025030399
Wang, M., Liang, R., Liu, Z., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7490141/v1
Belantamab mafodotin for the treatment of multiple myeloma
Oriol, A., Ibarra, G., Loscos, J., & Abril, L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2576502
Huang, X., Jayabalan, D. S., Liberto, M. D., Chen, Z., Ely, S. A., Mark, T. M., Lin, G., Niesvizky, R., & Chen‐Kiang, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.14.681840
“Despite a high overall response rate, patients treated with these agents alone rarely achieve complete remission; however, when given with proteasome inhibitors or antibodies to CS-1 or CD38, some MM patients enjoy robust, deep, and long complete responses 1, 2, 3, 4, 5 .”
Li, J., Melsew, Y. A., Wellard, C. J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.013
Self-citationIto, S., Hamada, T., Nakagawa, M., Ichinohe, T., Nukariya, H., Endo, T., Kurihara, K., Takeuchi, Y., Otake, S., Takahashi, H., et al. (2025) · Hematology Reports · doi:10.3390/hematolrep17060057
“Additionally, a recent study showed positive outcomes with a four-drug induction therapy, including daratumumab, bortezomib, lenalidomide, and dexamethasone, followed by ASCT, and maintenance therapy with daratumumab and lenalidomide [25].”
Hu, B., Wang, J., Fang, D., Jiang, L., Li, T., & Cao, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1619115
“…study (16, 17) — and the elevated incidence of hematologic toxicities (e.g., neutropenia, thrombocytopenia) and infections (e.g., pneumonia) (18), some experts remain cautious about universally recommending quadruplet regimens for all NDMM patients, resulting in a lack of de fi nitive…”
InfluentialSelf-citationSonneveld, P. (2025) · Hemato · doi:10.3390/hemato6040039 · Cited by 1
“…antibodies (daratumumab and isatuximab), resulting in higher response rates, better quality of responses, higher rates of minimal residual disease (MRD) negativity, longer progression-free survival (PFS), and improved overall survival (OS) when compared with conventional chemotherapy [1,2].”
Self-citationMorè, S., Offidani, M., Corvatta, L., Zà, T., Fazio, F., Gherardini, M., Bongarzoni, V., Anaclerico, B., Franceschini, L., Ferraro, S., et al. (2025) · Cancers · doi:10.3390/cancers17213580
“…status has been used to discontinue consolidation therapy, as in the phase II MASTER trial [51]; to guide decisions regarding post-induction autologous stem cell transplantation, as in the phase III MIDAS study [52]; and to de-escalate maintenance therapy, as demonstrated in the PERSEUS trial [53].”
Return to employment outcomes in patients with multiple myeloma
Lilli, N. L., Pequin, M., Dulondel, L., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70257
Self-citationPuertas, B., Alejo, E., Pérez, J. J., Serra-Toral, F., Padilla, I., Dávila, J., García‐Mateo, A., Alonso, J. M., Hernández, R. S., Aguilar-Franco, C., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.11.007
Redefining Cure in Multiple Myeloma: Are We Chasing a Moving Target?
Kitundu, J. H. (2025) · Health Science Reports · doi:10.1002/hsr2.71581 · Cited by 2
Overcoming Renalism: A Roadmap Towards Equitable Kidney Care
Divyaveer, S. S., Anandh, U., Vijayakumar, N. A., Venkatasubramanian, V., & Hiremath, S. S. (2025) · Indian Journal of Nephrology · doi:10.25259/ijn_119_2025
Fatobene, G., Vergueiro, C. S. V., Simione, A. J., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.12.001
Luo, S., Wang, C., Wang, W., Wang, M., Yang, M., Deng, J., Fayed, B. E., Wang, H., Mei, H., Hu, D., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-8174877/v1
Aktuelle Fortschritte und neue Therapieoptionen in der Immunonkologie
Kobold, S., & Müller, R. (2025) · TumorDiagnostik & Therapie · doi:10.1055/a-2736-7079
Multiple Myeloma in Young Adults—Insights From a Tertiary Care Cancer Centre in India
John, G., Mirgh, S. P., Punatar, S. B., Jindal, N., Nayak, L., Chichra, A., Shetty, A., Gokarn, A. G., Rajpal, S., Patkar, N. V., et al. (2025) · eJHaem · doi:10.1002/jha2.70187
“Our findings align with global trials such as GRIFFIN, PERSEUS, and IFM, which also report improved survival rates with VRd, especially when combined with ASCT [26, 27, 28].”
Real-world evidence of measurable residual disease assessment in multiple myeloma
Cedena, M., Puig, N., Paiva, B., de la Puerta, J.-E., Pérez-Montaña, A., Casanova, M., Atienza, J. B., García, A., de Arriba, F., Martínez‐Chamorro, C., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025018454
“25 The same principle applies to the methodology.”
Bridging the Gap: Refining Myeloma Precursors and Their Risk of Progression Through Genomics
Saldarriaga, M. M., & Bellman, P. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-02305
Wang, T., Cui, S., Wang, J., Liu, Z., Liu, K., Wang, Z., Tang, X. T., Liu, D., Wang, Y., & Xu, R. (2025) · eJHaem · doi:10.1002/jha2.70195
“When available, daratumumab combined with bortezomib, thalidomide, and dexamethasone (D-VTd) represents the standard regimen for induction and consolidation [29].”
Self-citationMore than an emotional support PET
Hillengaß, J. (2025) · Blood · doi:10.1182/blood.2025031179
Wang, Y., Zhang, L., Dong, H., Chen, H., Zhang, H., Yuan, Y., Zhang, C., Feng, R., Wei, Y., & Wei, X. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100189 · Cited by 1
“The final analysis included 5588 patients with NDMM, of whom 915 had HRMM.”
InfluentialStrotmann, A., Leitner, T., Mazzeo, P., Evers, G., Pohlmann, A., Eisfeld, C., Seib, M., von Bubnoff, N., Lenz, G., Shumilov, E., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.008
Klomberg, K. M., Gelderloos, M., Kooistra, H. A. M., Nijland, M., de Bock, G. H., Huls, G. A., Brink, M., Roeloffzen, W. W. H., & Plattel, W. J. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.007
Self-citationZammar, G., Augustson, B., Moore, E., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.005
Self-citationHu, B., Fang, D. H., Jiang, L., Li, T., Chen, K., Cao, J., & Wang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1744165 · Cited by 1
Self-citationShah, I. A., Yadav, D. D., Khetrapal, B. D. A., et al. (2026) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2026.101267
Puig, N., Puertas, B., Padilla, I., Alejo, E., Serra-Toral, F., García‐Mateo, A., López-López, R., Bárez, A., Alonso, J. M., Aguilar-Franco, C., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8444748/v1
Leonhardi, J., Dermendzhiev, T., Bach, E., Brückner, M., Wang, S., Franke, G., Jentzsch, M., Heyn, S., Metzeler, K. H., Platzbecker, U., et al. (2026) · Transfusion Medicine and Hemotherapy · doi:10.1159/000549972
“All but one patient in our cohort were treated with a quadruplet induction therapy with daratumumab, bortezomib, thalidomide, and dexamethasone (DaraVTd) in analogy to the CASSIOPEIA phase III trial; the remaining patient was treated with isatuximab-based regimen [4].”
InfluentialHigh CTC, high-risk cytogenetics: a dangerous duo in MM?
Shain, K. H., & Baz, R. (2026) · Blood · doi:10.1182/blood.2025031606
Cebulla, N., Schirmer, D., Runau, E., Flamm, L., Terhorst, C., Jähnel, L., Güse, J., Giordani, N., Wieser, A., Schoch, F., et al. (2026) · Journal of the Peripheral Nervous System · doi:10.1111/jns.70090
“In clinical practice, BTZ is often combined with CD38 antibodies (daratumumab/isatuximab), immunomodulatory drugs (thalidomide, lenalidomide, or pomalidomide), and corticosteroids (prednisolone or dexamethasone) [6, 7].”
Self-citationMohan, M., Radhakrishnan, S. V., Schinke, C., Katodritou, E., & Fonseca, R. (2026) · American Journal of Hematology · doi:10.1002/ajh.70215
“The recent PERSEUS study, which employed a 16-week induction course, reported 75% MRD negativity in those with a complete response or better [2].”
Self-citationHughes, M. S., & Lentzsch, S. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2619438
“The MASTER trial reported the same in a prospective population a priori enriched for ‘high-risk’ disease, and the PERSEUS and CASSIOPEIA trials confirmed the finding [49–52].”
Sheng, X., Zheng, Q., Xiang, J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8603508/v1
Chen, M., Chen, G., Xu, J., Zhang, K., Yang, R., Han, C., Hou, J., Jiang, M. Y., & Yuan, H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1680704
“(15).”
Zhu, Z., Li, X., Chen, X., Yuan, X., Lin, T., & Li, N. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102075
Lenalidomide maintenance after delayed or salvage autologous stem cell transplantation
Haider, A. A., Marcoux, C., Milton, D. R., Tanner, M. R., Bashir, Q., Smallbone, P., Srour, S. A., Saini, N. Y., Lin, P., Ramdial, J., et al. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2619498
Landgren, O., Abonour, R., & Kazandjian, D. G. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.01.002 · Cited by 3
You, J., Zhang, Y., Meng, Y. G., et al. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207261417132
Sretenović, A., Mitrovic, M., Bukumirić, Z., Vukosavljevic, N., Kecman, N., Jovanović, J., Fekete, M. D., Zaric, E., & Bila, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1765235
“In this context, the PERSEUS and CEPHEUS phase III trials established daratumumab-VRd (D-VRd) quadruplets as a new standard in the frontline setting for transplant-eligible and transplant-ineligible, overcoming the inferior outcome of the high-risk pts including those with 1q21 CAs (38, 39).”
Alam, F., Siddiqui, H., Nihal, A., Andleeb, M., Zaman, A. Q. U., Khushk, M. I., Hussain, F., Rai, R., Fatima, F., Kumar, D., et al. (2026) · World Journal of Methodology · doi:10.5662/wjm.v16.i1.107864
Dimopoulos, M. A., Boccadoro, M., Einsele, H., Rodríguez‐Otero, P., Hulin, C., Perrot, A., Leleu, X. P., Caillot, D., Facon, T. T. F., Mina, R., et al. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2624972
Self-citationPasvolsky, O., Marcoux, C., Milton, D. R., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P., Siddiqui, U. R., Khan, H., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.02.014
Côté, J. A., Desforges, P., Dionne, C., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1632275
“Moreover, many of these therapies may lead to cognitive decline which can hinder proper assessment and subsequent treatment of patients (28, 29, 39).”
Aughey, E., Estrada‐Merly, N., Akhtar, O. S., Dhakal, B., Mohan, M., Narra, R. K., Pasquini, M. C., & D’Souza, A. (2026) · British Journal of Haematology · doi:10.1111/bjh.70428
Cheng, L., Liang, D., Jia, J. L., Zhang, R., Yang, Y., Liu, P., Sun, H., Qin, X., Ma, Y., Wu, Y., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-15815-8
“In patients with only del(17p), t(14;16), t(4;14), or these plus 1q21+, rates were 39% (D-VRd) and 29.4% (VRd), still much higher than RCT studies [4, 19].”
InfluentialLouzada, M., Reece, D. E., Venner, C. P., White, D. J., Su, J., Chu, M. P., Zepeda, V. H. J., McCurdy, A. B. R., Song, K., Mian, H. S., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100215
“29,30 In CEPHEUS, dara-RVd was compared with RVd (control) in TIMM.”
Maintenance intensification after autologous HSCT: refining selection
Perrot, A., & Frenzel, L. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(26)00064-5
Self-citationRamanan, S. P., Abioye, O. F., Atrash, S., Wu, J., Mudaranthakam, D. P., Mazloom, A., Alkharabsheh, O. A., Shah, M. R., Mahmoudjafari, Z., Snyder, J. A., et al. (2026) · Current Oncology · doi:10.3390/curroncol33030164
“The PERSEUS trial demonstrated that adding dara-tumumab to VRd induction and consolidation, followed by daratumumab–lenalidomide maintenance, significantly reduced the risk of progression or death compared to VRd followed by lenalidomide alone in transplant-eligible patients [15].”
Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma
Schlusemann, T., Shumilov, E., Reinartz, G., Steike, D. R., Lohmann, S., Gravemeyer, S., Stelljes, M., Lenz, G., Eich, H. T., & Oertel, M. (2026) · Hematological Oncology · doi:10.1002/hon.70186
Ocio, E. M., & Mateos, M. T. Á. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.004
Davis, J. A., McElwee, J., Gonzalez, R. M., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100220
Mele, G., Palmieri, S., Rocco, S., et al. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2645942
“Both trials reported a lower median Cd34 + cell yield in the d-rVd arm compared to the rVd control arm [9,10], suggesting that the well known suppressive effect on PBSC collection due to the use of lenalidomide-based induction therapies [11] may be further exacerbated by the concomitant use of…”
Liu, Y., Lee, J. H., Mo, C. C., Salman, T. J., Hossain, S., Midha, S., Nadeem, O., Nicholson, T., Croteau, J., Kazierad, N., et al. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2646947 · Cited by 3
“Thus, the MRD-adaptive treatment approaches that have emerged recently in the NDMM setting [293,294] will potentially become increasingly applicable in RRMM treatment.”
Self-citationChoosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection
Hadidi, S. A., Costello, C. L., Costa, L. J., Dhakal, B., Georges, P., Gajra, A., Lin, Y., Bhargava, R. S., Paner-Straseviciute, A., & Vij, R. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.009 · Cited by 1
Mehanna, N., Derkach, A., Gasmi, B., Anagnostou, T., Landau, H. J., Lahoud, O. B., Scordo, M., Shah, G. L., Hassoun, H., Maclachlan, K. H., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100221
“8,34,35 Our finding that CD38 expression is higher among ER patients at multiple time points, in conjunction with clinical data demonstrating the benefit of CD38 mAbs during induction and maintenance treatment phases, raises the possibility that CD38 CD8 T cells for identifying early relapse.”
Röhnert, M. A., Seifert, A., Trautmann‐Grill, K., Röllig, C., Zimmer, K., Egger‐Heidrich, K., Bill, M., Heberling, L., Schulze, F., Blechschmidt, M., et al. (2026) · Transfusion · doi:10.1111/trf.70165 · Cited by 1
“5,28,29 32 In the large phase III ReLapse trial, salvage ASCT was not superior to conventional salvage therapies.”
Suzuki, K., Matsumoto, M., Takamatsu, H., Kosugi, H., Kondo, T., Fujisaki, T., Facon, T. T. F., Zweegman, S., Ito, M., Sakai, C., et al. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04185-3
“This trial showed that the D-VRd regimen increased the depth of response and significantly improved PFS compared with VRd [16].”
InfluentialSelf-citationImpact of CYP and ABCB1 Polymorphisms on Bortezomib-Induced Adverse Events in Multiple Myeloma
Sanz-Solas, A., Pérez-Gómez, N., Labrador, J., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14040805
“…induction therapy with bortezomib (BTZ), lenalidomide, and dexamethasone (VRD), followed by autologous stem cell transplantation, consolidation therapy with VRD, and maintenance therapy with lenalidomide are considered standard care for transplantation-eligible patients with newly diagnosed MM [4].”
Lau, G., Chandra, M. B., Fero, H., & Alabbas, F. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04195-1 · Cited by 1
Novellis, D. D., Fontana, R., Rizzo, M., Carobene, A., Morini, D., Serio, B., Guariglia, R., Luponio, S., Langella, M., Verdesca, F., et al. (2026) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2026.104430
Inoue, Y., Harada, T., Oda, A., Ohara, N., Nakagawa, H., Urushihara, M., Nakao, T., & Matsuoka, K.-I. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04210-5
“Recently, therapeutic regimens incorporating DARA or ISA during induction, consolidation, and maintenance phases have been developed and shown to achieve stringent complete remission and MRD negativity [18–20].”
Larue, M., Ferment, B., Allain, V., Fadlallah, J., Hervier, B., Arnulf, B., & Talbot, A. (2026) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2026.03.441
Metadata
- Authors
- Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Nijhof, I. S., van de Donk, N. W. C. J., Katodritou, E., Schjesvold, F., Sureda Balari, A., Rosiñol, L., Delforge, M., Roeloffzen, W., Silzle, T., Vangsted, A., Einsele, H., Spencer, A., Hajek, R., Jurczyszyn, A., Lonergan, S., Ahmadi, T., Liu, Y., Wang, J., Vieyra, D., van Brummelen, E. M. J., Vanquickelberghe, V., Sitthi-Amorn, A., de Boer, C. J., Carson, R., Rodriguez-Otero, P., Bladé, J., & Moreau, P.
- Affiliations
- University Medical Center Groningen (NL)
- The University of Sydney (AU)
- From the Department of Hematology, Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) — all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) — both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi ...
- Oslo University Hospital (NO)
- Jagiellonian University (PL)
- ORCID
- Sonneveld, Pieter
- Dimopoulos, Meletios A.
- Boccadoro, Mario
- Quach, Hang
- Ho, P. Joy
- Hulin, Cyrille
- Antonioli, Elisabetta
- Leleu, Xavier
- Mangiacavalli, Silvia
- Perrot, Aurore
- Belotti, Angelo
- Broijl, Annemiek
- Gay, Francesca
- Mina, Roberto
- Katodritou, Eirini
- Schjesvold, Fredrik
- Rosiñol, Laura
- Delforge, Michel
- Roeloffzen, Wilfried
- Silzle, Tobias
- Vangsted, Annette
- Einsele, Hermann
- Spencer, Andrew
- Jurczyszyn, Artur
- Ahmadi, Tahamtan
- Liu, Yanfang
- Wang, Jianping
- Sitthi-Amorn, Anna
- Bladé, Joan
- Moreau, Philippe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-01-25
- Volume
- 390
- Issue
- 4
- Pages
- 301-313
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4389606680
- Cited by
- 599
- References
- 23
- Citations by year
- 2026: 198 · 2025: 252 · 2024: 145
- FWCI
- 123.04
- Type
- journal article
- Language
- en
- Open access
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- European Myeloma Network in collaboration with Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- multiple myeloma, daratumumab, bortezomib, lenalidomide, dexamethasone, subcutaneous daratumumab, CD38, newly diagnosed multiple myeloma, progression-free survival, minimal residual disease, complete response, lenalidomide maintenance, neutropenia
- MeSH terms
- Bortezomib, Lenalidomide, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Membrane Glycoproteins, Multiple Myeloma, Disease Progression, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


